EFPEGLENATIDE
Total Payments
$3.9M
Transactions
1,374
Doctors
39
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $3.9M | 1,344 | 32 |
| 2018 | $9,700 | 28 | 12 |
| 2017 | $880.24 | 2 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.9M | 1,345 | 99.9% |
| Consulting Fee | $3,240 | 8 | 0.1% |
| Food and Beverage | $248.84 | 20 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $48.50 | 1 | 0.0% |
Payments by Type
Research
$3.9M
1,345 transactions
General
$3,537
29 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia | SANOFI US SERVICES INC. | $1.8M | 18 |
| A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | SANOFI US SERVICES INC. | $1.4M | 2 |
| A 30-week, multicenter, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of efpeglenatide once weekly in patients with Type 2 diabetes mellitus inadequately contr | SANOFI US SERVICES INC. | $454,512 | 0 |
| A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr | SANOFI US SERVICES INC. | $183,095 | 0 |
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea | SANOFI US SERVICES INC. | $58,857 | 1 |
| A PHASE II, 12-WEEK, DOUBLE-BLIND, RANDOMISED, PARALLEL GROUP, MULTI-CENTRE, INTERNATIONAL TRIAL TO ASSESS THE EFFECT ON GLYCAEMIC CONTROL OF FIVE DOSES OF HM11260C VERSUS PLACEBO OR OPEN-LABEL LIRAGL | SANOFI-AVENTIS U.S. LLC | $8,078 | 3 |
| A phase 2, 12-week, double-blind, randomised, parallel group, multicentre, international trial to assess the effect on glycaemic control of five doses of efpeglenatide (HM11260C) versus placebo or ope | SANOFI-AVENTIS U.S. LLC | $3,697 | 2 |
| A 20-week, double-blind, randomised, placebo-controlled, parallel-group trial to assess the safety and efficacy of efpeglenatide (HM11260C) on body weight in obese subjects without diabetes | SANOFI-AVENTIS U.S. LLC | $3,482 | 1 |
| A 20-WEEK, DOUBLE-BLIND, RANDOMIZED,,PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS,THE SAFETY AND EFFICACY OF HM11260C ON BODY WEIGHT IN,OBESE SUBJECTS WITHOUT DIABETES (HM-EXC-205) | SANOFI-AVENTIS U.S. LLC | $2,667 | 1 |
Top Doctors Receiving Payments for EFPEGLENATIDE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $3.8M | 1,238 |
| , D.O | Internal Medicine | Pembroke Pines, FL | $54,407 | 6 |
| , MD | Geriatric Medicine | Orlando, FL | $8,003 | 16 |
| , M.D | Endocrinology, Diabetes & Metabolism | Dallas, TX | $6,238 | 13 |
| , M.D | Endocrinology, Diabetes & Metabolism | La Jolla, CA | $3,732 | 10 |
| , D.O | Family Medicine | Charleston, SC | $2,230 | 4 |
| , M.D | Internal Medicine | Burke, VA | $2,076 | 4 |
| , DO | Family Medicine | Spring Valley, CA | $1,969 | 4 |
| , MD | Family Medicine | Tucson, AZ | $1,930 | 4 |
| , M.D | Internal Medicine | Birmingham, AL | $1,840 | 4 |
| , MD | Family Medicine | Layton, UT | $1,819 | 4 |
| , M.D | Internal Medicine | Chandler, AZ | $1,794 | 4 |
| , MD | Internal Medicine | Bridgeton, NJ | $1,784 | 4 |
| Kurt Lesh | — | Colorado Spgs, CO | $1,743 | 4 |
| , M.D | Internal Medicine | Maumee, OH | $1,715 | 4 |
| , MD | Cardiovascular Disease | Stanford, CA | $1,690 | 3 |
| , M.D | Internal Medicine | Burke, VA | $1,626 | 4 |
| , MD | Internal Medicine | Wilbraham, MA | $1,617 | 4 |
| , MD | Internal Medicine | San Diego, CA | $1,585 | 4 |
| Sam Miller | — | San Antonio, TX | $1,568 | 2 |
| , M.D., PH.D | Neurocritical Care | Baltimore, MD | $1,550 | 5 |
| , D.O | Family Medicine | Orlando, FL | $1,282 | 3 |
| , M.D | Internal Medicine | Maumee, OH | $1,248 | 3 |
| , MD | Internal Medicine | Coral Gables, FL | $1,000 | 2 |
| , M.D | Internal Medicine | San Antonio, TX | $710.00 | 1 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $3.9M
- SANOFI-AVENTIS U.S. LLC $18,222
Product Information
- Type Drug
- Total Payments $3.9M
- Total Doctors 39
- Transactions 1,374
About EFPEGLENATIDE
EFPEGLENATIDE is a drug associated with $3.9M in payments to 39 healthcare providers, recorded across 1,374 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2019. In 2019, $3.9M was paid across 1,344 transactions to 32 doctors.
The most common payment nature for EFPEGLENATIDE is "Unspecified" ($3.9M, 99.9% of total).
EFPEGLENATIDE is associated with 9 research studies, including "A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia" ($1.8M).